Abstract
Erectile dysfunction (ED) is often associated with cardiovascular disease (CVD) and the risk of sildenafilinduced orthostatic hypotension (OH) in subjects with CVD is a matter of concern. We describe our experience in using the tilt test (TT) with continuous plethysmography to evaluate the occurrence of OH in patients with CVD and ED after a test dose of sildenafil. When sildenafil was added on top of their usual pharmacological treatment two patients out of 32 (6.2%) developed asymptomatic OH, with a maximum blood pressure fall of 40/20 mm Hg. The low prevalence and modest clinical relevance of OH in our high-risk population coupled with the known high sensitivity and reproducibility of the TT seem to suggest that sildenafil is haemodynamically safer than is generally believed even when added on top of vasoactive treatment. These findings should be put into perspective against the growing wealth of evidence that PDE5 inhibitors may have therapeutic potential for a number of CV conditions.
Keywords: Erectile disfunction, sildenafil, orthostatic hypotension, drug safety, cardiovascular disease, Tilt Test, Plethysmography, PDE5 inhibitors
Current Drug Safety
Title: Limited Hypotensive Effect of Sildenafil in a High-Risk Population: A Preliminary Report
Volume: 6 Issue: 4
Author(s): M. M. Ciulla, P. Nicolini, C. Benfenati, C. Vecchiato, G. Acquistapace, G. L. Perrucci and F. Magrini
Affiliation:
Keywords: Erectile disfunction, sildenafil, orthostatic hypotension, drug safety, cardiovascular disease, Tilt Test, Plethysmography, PDE5 inhibitors
Abstract: Erectile dysfunction (ED) is often associated with cardiovascular disease (CVD) and the risk of sildenafilinduced orthostatic hypotension (OH) in subjects with CVD is a matter of concern. We describe our experience in using the tilt test (TT) with continuous plethysmography to evaluate the occurrence of OH in patients with CVD and ED after a test dose of sildenafil. When sildenafil was added on top of their usual pharmacological treatment two patients out of 32 (6.2%) developed asymptomatic OH, with a maximum blood pressure fall of 40/20 mm Hg. The low prevalence and modest clinical relevance of OH in our high-risk population coupled with the known high sensitivity and reproducibility of the TT seem to suggest that sildenafil is haemodynamically safer than is generally believed even when added on top of vasoactive treatment. These findings should be put into perspective against the growing wealth of evidence that PDE5 inhibitors may have therapeutic potential for a number of CV conditions.
Export Options
About this article
Cite this article as:
M. Ciulla M., Nicolini P., Benfenati C., Vecchiato C., Acquistapace G., L. Perrucci G. and Magrini F., Limited Hypotensive Effect of Sildenafil in a High-Risk Population: A Preliminary Report, Current Drug Safety 2011; 6 (4) . https://dx.doi.org/10.2174/157488611798280898
DOI https://dx.doi.org/10.2174/157488611798280898 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diamidine Activity Against Trypanosomes: The State of the Art
Current Molecular Pharmacology Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology Editorial: Cures of Vascular Disease - The State
Current Vascular Pharmacology Chiral Kinase Inhibitors
Current Topics in Medicinal Chemistry Quinazolin-4-One: A Varsatile Molecule
Current Bioactive Compounds New Developments in the Diagnosis and Management of Resistant Hypertension
Current Medicinal Chemistry The Use of Dexmedetomidine in Anesthesia and Intensive Care: A Review
Current Pharmaceutical Design Neurokinin-1 (NK<sub>1</sub>) receptor antagonists as possible therapeutics for psychostimulant use disorders
CNS & Neurological Disorders - Drug Targets Initiation of Dialysis: A Mini-Review of a Changing Paradigm
Cardiovascular & Hematological Disorders-Drug Targets Gastrointestinal Dysmotility and Infections in Systemic Sclerosis- An Indian Scenario
Current Rheumatology Reviews Vcsa1 Gene Peptides for the Treatment of Inflammatory and Allergic Reactions
Recent Patents on Inflammation & Allergy Drug Discovery Regulation of Adrenomedullin and its Family Peptide by RAMP System – Lessons from Genetically Engineered Mice
Current Protein & Peptide Science Biomedical Applications of Poly(Lactic Acid)
Recent Patents on Regenerative Medicine The Role of Niacin in Lipid-lowering Treatment: Are we Aiming Too High?
Current Pharmaceutical Design Cyclodextrin Based Nanosponges: A Multidimensional Drug Delivery System and its Biomedical Applications
Current Drug Delivery Can Tea Consumption be a Safe and Effective Therapy Against Diabetes Mellitus-Induced Neurodegeneration?
Current Neuropharmacology Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Current Neuropharmacology Hypotensive Peptides from Snake Venoms: Structure, Function and Mechanism
Current Topics in Medicinal Chemistry Loop Diuretics Strategies in Acute Heart Failure: From Clinical Trials to Practical Application
Current Drug Targets Nutraceuticals and their Novel Drug Delivery System: A Boon to Human Health
Current Nutrition & Food Science